胸腺肽α1用于恶性肿瘤治疗对机体免疫功能影响的观察

Preliminary application of Thymosin α1 in the treatment of malignant tumor

目的 观察胸腺肽α1在恶性肿瘤治疗中的价值。方法 15例胸腺肽α1治疗组 :胸腺肽α1用法为 1.6mg/次 ,皮下注射 ,每周 2次 ,中位疗程为 3.5个月。以外周血T淋巴细胞核仁形成区嗜银蛋白 (Ag NORs)含量 (I .S %值 )作为为评价机体免疫功能状况的指标。对照组 :15例正常人。未治疗组 :15例恶性肿瘤但未接受胸腺肽α1治疗患者 ;对其45例外周血T淋巴细胞Ag NORs含量进行检测 ,并对治疗组应用胸腺肽α1前后的Ag NORs含量进行动态观察。结果 正常人外周血T淋巴细胞Ag NORs含量显著高于治疗组和未治疗组患者 (P <0 .0 1) ,而治疗组与未治疗组间无显著差异(P >0 .0 5 ) ;治疗组患者应用胸腺肽α1后Ag NORs含量较用药前明显提高 (P <0 .0 5 )。结论 恶性肿瘤患者存在明显的免疫功能下降 ,应用胸腺肽α1可调节和提高肿瘤患者的细胞免疫功能。

Objective To evaluate the clinical significance of Thymosin α1 in the treatment of malignant tumor.Methods 15 patients were treated with Thymosin α1(Treatment group)with doses of 1.6mg subcutaneous injection twice weekly,with a median course of 3.5 months.The number of Ag-NORs of peripheral blood T lymphocyte was used as a marker for monitoring immune activity.The number of Ag-NORs was detected in 15 cases of health controls,15 patients in Treatment group and 15 patients with malignant tumor without use of Thymosin α1(Non-treatment group).The dynamic variation of the number of Ag-NORs before and after administration of Thymosin α1 in Treatment group were evaluated.Results The number of Ag-NORs of peripheral blood T lymphocyte in health controls was higher than that in Treatment group and Non-treatment group(P<0.01).No significant difference of the number of Ag-NORs between Treatment group and Non-treatment was found(P>0.05).The number of Ag-NORs after administration of Thymosin α1 was higher than that before administration (P<0.05).Conclusion Patients with malignant tumor show significant immunodeficiency compared with healthy controls and Thymosin α1 may play a role in regulating and enhancing cellular immune activity in patients with malignant tumor.